The episode explores the primary concern associated with GLP-1 agonists: the loss of muscle mass that accompanies significant weight loss. While patients experience overall functional improvements (e.g., mobility, VO2 max), the reduction in absolute strength and muscle mass presents a potential long-term health risk that the pharmaceutical industry is trying to address.
The conversation details the industry's response to the muscle loss problem, focusing on the development of myostatin inhibitors. These drugs aim to either preserve muscle during weight loss or treat age-related sarcopenia, representing a new frontier in pharmacological interventions for maintaining physical function.
A significant portion of the discussion speculates on the stringent requirements the FDA will impose for approving drugs that treat sarcopenia or prevent muscle loss. The speaker argues that the agency will not approve a drug based solely on increased lean body mass or improved insulin sensitivity, but will demand clear evidence of enhanced functional outcomes, specifically absolute strength.
The speaker critiques the current methodologies for assessing physical function in clinical trials, specifically calling the six-minute walk test "stupid." The discussion differentiates between relative strength (which improves with weight loss) and absolute strength (which may decline), arguing that the latter is a more meaningful measure of a patient's real-world capabilities and should be the focus of evaluation.
Keep pulling the thread on Dr. Ralph DeFronzo.